NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
14 trialsNCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06550141 2025-11-14
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Phase 2 Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03942224 2024-06-21
DeRIVE
Emory University
Phase 2 Active not recruiting
NCT06455072 2024-06-12
Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer
Fujian Cancer Hospital
Phase 2 Recruiting
NCT01873833 2023-10-05
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
University of Southern California
Phase 2 Terminated
NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT01335009 2021-09-01
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Eisai Inc.
Phase 2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT01136395 2019-10-08
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
University of Giessen
Phase 2 Completed
NCT00310128 2016-02-03
Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma
AIDS Malignancy Consortium
Phase 2 Withdrawn
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00265928 2008-01-28
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Terminated